Protagonist raises $22M to revive PTG-100; Paratek's antibiotic shows non-inferiority
→ Protagonist Therapeutics {PTGX}, a tiny public company in Newark, CA, has inked a securities purchase deal totaling $22 million in shares to sort out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
